Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net loss attributable to Adaptive Biotechnologies Corporation	$ (207,279)	$ (146,227)	$ (68,606)
Fair value adjustment to redemption value for Series E-1 convertible preferred stock options			(964)
Net loss attributable to Adaptive Biotechnologies Corporation common shareholders	$ (207,279)	$ (146,227)	$ (69,570)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	140,354,915	131,216,468	69,165,315
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$ (1.48)	$ (1.11)	$ (1.01)